Israel
· Delayed Price · Currency is ILS · Price in ILA Enlivex Therapeutics Company Description
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis.
The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial.
Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
| Country | Israel |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Oren Hershkovitz |
Contact Details
Address: 14 Einstein Street Ness Ziona, 7403618 Israel | |
| Phone | 972 2 670 8072 |
| Website | enlivex.com |
Stock Details
| Ticker Symbol | ENLV |
| Exchange | Tel Aviv Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | IL0011319527 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer |
| Shai Novik M.B.A. | Executive Chairman |
| Prof. Dror Mevorach M.D. | Founder and Scientific Advisor |
| Shachar Shlosberger CPA | Chief Financial Officer |
| Dr. Veronique Amor-Baroukh | Senior Director of Operations |
| Sigal Arad | Director of Human Resources |
| Dr. Einat Galamidi M.D. | Chief Medical Officer |